NEC OncoImmunity AS
🇳🇴Norway
- Country
- 🇳🇴Norway
- Ownership
- Subsidiary
- Established
- 2014-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.oncoimmunity.com
Clinical Trials
1
Active:1
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)NECVAX-NEO1 in Addition to Checkpoint Inhibitor in Patients With Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Solid Tumors, Adult
- Interventions
- Biological: NECVAX-NEO1
- First Posted Date
- 2022-04-29
- Last Posted Date
- 2025-06-26
- Lead Sponsor
- NEC OncoImmunity AS
- Target Recruit Count
- 6
- Registration Number
- NCT05354323
- Locations
- 🇱🇹
Kaunas University Hospital, Kaunas, Lithuania
🇱🇹National Cancer Institute, Vilnius, Lithuania
🇱🇹Vilnius University Hospital Santaros Clinics, Vilnius, Lithuania
News
No news found